{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:38:32Z","timestamp":1792013912764,"version":"4.4.0"},"reference-count":42,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Chongqing Science & Technology Platform and Base Construction Program","award":["cstc2014pt-sy10002"],"award-info":[{"award-number":["cstc2014pt-sy10002"]}]},{"name":"Chongqing Outstanding Science Project"},{"name":"Natural Science Foundation Major International (Regional) Joint Research Project","award":["81720108009"],"award-info":[{"award-number":["81720108009"]}]},{"name":"National Natural Science Foundation Key Program","award":["81930023"],"award-info":[{"award-number":["81930023"]}]},{"name":"Chongqing Key Laboratory of Ophthalmology","award":["CSTC, 2008CA5003"],"award-info":[{"award-number":["CSTC, 2008CA5003"]}]},{"name":"Chongqing Chief Medical Scientist Project"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Chronic Disease"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The application of biologic agents has benefited patients with Behcet\u2019s uveitis (BU) who do not respond to conventional treatment regimens. However, there is currently no consensus on the optimal treatment regimen of interferon alpha-2a (IFN-\u03b12a) for refractory BU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate treatment outcomes and safety of IFN-\u03b12a in a large series of refractory BU patients and to explore whether nonbiologic immunomodulatory agents (cyclosporin A) other than corticosteroids should be concomitantly used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study, which included 153 BU patients who received IFN-\u03b12a treatment between December 2012 and September 2023 with a minimum duration of 6\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Best-corrected visual acuity (BCVA), the frequency of uveitis relapse, corticosteroid-sparing effect, and side effects were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 153 patients enrolled, 87 patients were treated with IFN-\u03b12a plus corticosteroids (IC), and 66 patients were treated with IFN-\u03b12a plus corticosteroids and cyclosporin A (ICC). Both IFN-\u03b12a treatment regimens significantly improved BCVA as early as 2\u2009months following treatment, and the improvement was maintained over at least a 2-year follow-up. At the final visit, 86.8% and 73.1% of the affected eyes in the ICC and IC groups achieved improved or stable vision, respectively. The ICC regimen was more effective at improving vision ( p\u2009=\u20090.01). Overall, the frequency of uveitis relapse and the dose of oral prednisolone were significantly reduced in both groups after treatment (all p\u2009&lt;\u20090.0001). However, there were no statistically significant differences in these parameters between the two groups. None of the included patients experienced serious side effects that led to the discontinuation of IFN-\u03b12a therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>IFN-\u03b12a treatment is a promising option for patients with refractory BU. Our results showed that cyclosporin A as an adjunct could enhance the therapeutic effect of IFN-\u03b12a.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406223241304889","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T02:07:31Z","timestamp":1733969251000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Cyclosporin A as an adjunct may enhance the therapeutic effect of interferon alpha-2a in patients with refractory Behcet\u2019s uveitis: a retrospective cohort study"],"prefix":"10.1177","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2647-6619","authenticated-orcid":false,"given":"Peizeng","family":"Yang","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Chongqing Medical University, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China"},{"name":"Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Henan Province Eye Hospital, Henan International Joint Research Laboratory for Ocular Immunology and Retinal Injury Repair, Zhengzhou, China"},{"name":"The Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Deng","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Chongqing Medical University, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Henan Province Eye Hospital, Henan International Joint Research Laboratory for Ocular Immunology and Retinal Injury Repair, Zhengzhou, China"},{"name":"The Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunYun","family":"Zhu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Chongqing Medical University, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqian","family":"Huang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Chongqing Medical University, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Dai","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Chongqing Medical University, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Wu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Chongqing Medical University, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guannan","family":"Su","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Chongqing Medical University, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Cao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Chongqing Medical University, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Lai","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Chongqing Medical University, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"bibr1-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2007.09.002"},{"key":"bibr2-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-014-8425-z"},{"key":"bibr3-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102920"},{"key":"bibr4-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100866"},{"key":"bibr5-20406223241304889","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.765377"},{"key":"bibr6-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0929-5"},{"key":"bibr7-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2019.02.002"},{"key":"bibr8-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.02.018"},{"key":"bibr9-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.11.022"},{"key":"bibr10-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1606256"},{"key":"bibr11-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1587473"},{"key":"bibr12-20406223241304889","first-page":"808","volume":"77","author":"Hatemi G","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"bibr13-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1177\/2040622319847881"},{"key":"bibr14-20406223241304889","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.699903"},{"key":"bibr15-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.4.423"},{"key":"bibr16-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2016.1206204"},{"key":"bibr17-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-315960"},{"key":"bibr18-20406223241304889","doi-asserted-by":"publisher","DOI":"10.2174\/1566524018666180207153342"},{"key":"bibr19-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12107"},{"key":"bibr20-20406223241304889","first-page":"1078","volume":"335","author":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","year":"1990","journal-title":"Lancet"},{"key":"bibr21-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"bibr22-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1384026"},{"key":"bibr23-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-3726-4"},{"key":"bibr24-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.04.056"},{"key":"bibr25-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.3"},{"key":"bibr26-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00767-0"},{"key":"bibr27-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.08.038"},{"key":"bibr28-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.3"},{"key":"bibr29-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0719-0"},{"key":"bibr30-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3318-6"},{"key":"bibr31-20406223241304889","first-page":"896","volume":"35","author":"Krause L","year":"2008","journal-title":"J Rheumatol"},{"key":"bibr32-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.08.031"},{"key":"bibr33-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.101550"},{"key":"bibr34-20406223241304889","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2015.1133835"},{"key":"bibr35-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1002\/art.27581"},{"key":"bibr36-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2012.09.003"},{"key":"bibr37-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205571"},{"key":"bibr38-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1007\/0-306-48382-3_102"},{"key":"bibr39-20406223241304889","doi-asserted-by":"publisher","DOI":"10.3109\/10611861003649746"},{"key":"bibr40-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0134-5"},{"key":"bibr41-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2020.1847271"},{"key":"bibr42-20406223241304889","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2003.09.005"}],"container-title":["Therapeutic Advances in Chronic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223241304889","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406223241304889","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223241304889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:20:05Z","timestamp":1777591205000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406223241304889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":42,"alternative-id":["10.1177\/20406223241304889"],"URL":"https:\/\/doi.org\/10.1177\/20406223241304889","relation":{},"ISSN":["2040-6223","2040-6231"],"issn-type":[{"value":"2040-6223","type":"print"},{"value":"2040-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"20406223241304889"}}